Online Products · Analytical Assays & Public-Health Surveillance Dispatch 06 · Melanotan I & II Online

Online Melanotan I and II: Underfilled containers, unidentified impurities, and “research only” labels

Outside prescription supply chains, the early academic names appear on internet storefronts, tanning salons, and social feeds—where published laboratory assays find mislabeled weights, unidentified impurities, and limited published testing of the products sampled.

Two tall unmarked borosilicate glass liquid chromatography columns held in brass clamps beside clean empty glass flasks and three square quartz optical cuvettes lined on a pale sunlit travertine laboratory bench with sharp geometric shadows.
Field Record 08 · Analytical Assay In an LC-UV-MS/MS analytical study of Melanotan II vials purchased from three online shops, Breindahl et al. (2015) measured total peptide contents below each shop's labeled weight and 4.1% to 5.9% unknown impurities in two shops.

From academic names to forums and social feeds

By 2010, dermatologists documented consumer use of unregulated products labeled melanotan I and/or II obtained via the internet, tanning salons, and gyms, noting nicknames such as “Barbie drugs” and “sun-tan jabs” alongside UK MHRA warnings over blood-borne virus risks from needle sharing and potential product impurity (Langan et al., 2010).

Qualitative and content studies document how consumers discuss these products online. Between January 2016 and October 2017, Gilhooley et al. (2021) extracted 623 discussion entries contributed by 205 participants on UK and Ireland forums, identifying themes of misinformation around an unregulated product, informal product preparation and dosing discussions, sunbed use, polypharmacy, potentially contaminated products, and infectious-disease risks. A content analysis cited by Vadner & Smith (2026) found that approximately 3% of analyzed pro-tanning TikTok videos referenced Melanotan II, including nasal spray and injectable formulations.

How UK and Australian regulators classify sprays and injections

National agencies address dosage forms differently under their own statutes:

  • UK MHRA (FOI 24/274, April 17, 2024): “Products containing Melanotan II are classified as medicines if they are injectable or pens. If a product contains Melanotan II and is in the form of a nasal spray, it will be determined as a medicine only if sold with claims to treat or prevent disease.” MHRA adds: “It is important to note that the sale, supply and advertising of unauthorised medicines is not permitted under the Human Medicines Regulations,” and notes that unauthorized products have unknown contents with “no safeguards that these products meet our standards for quality, safety or effectiveness.”
  • Australia TGA (January 24, 2025): “Melanotan is not approved for sale or use as a tanning agent in Australia. These tanning agents haven’t been assessed for their quality or safety.” “It is illegal to supply tanning products containing melanotan without a doctor’s prescription. These restrictions apply regardless of whether it is a spray, a tablet, an injection, a cream or in any other form.” “It is also illegal to advertise melanotan to the Australian public. This includes promotion by social media influencers.” “In 2023-24, the TGA requested the removal of over 4,800 unlawful advertisements of therapeutic goods from various digital platforms (including social media platforms).”

What analytical chemistry found inside sampled peptide products

Published laboratory investigations of online Melanotan II vials and confiscated illegal peptides document content shortfalls, unidentified impurities, toxic elements, and microbial contamination:

Published Analytical & Microbiological Audits of Online Melanotan II and Seized Illegal Peptides
Investigation Sample Scope Measured Analytical Finding Primary Source
LC-UV-MS/MS vial content & purity assay Melanotan II vials purchased from 3 online shops (each shop claiming 10 mg per vial) Measured total peptide mass 4.32–8.84 mg per vial; 4.1%–5.9% unknown impurities in 2 of 3 shops (3rd below LOQ) Breindahl et al. (2015)
Chemical & elemental impurity screen 10 most frequent falsified peptide drugs in Belgium from 3 suspected illegal internet pharmacies 5%–75% purity (cysteine-containing peptides); lead (Pb) in 1 sample; inorganic arsenic (As) up to 10× ICH parenteral limit Janvier et al. (2018, Talanta)
Microbial sterility case report Illegal injectable polypeptide drugs analyzed in Belgium Hemolytic Bacillus cereus isolated from 2 illegal injectable peptide drugs Janvier et al. (2018, Drug Test Anal)
Pharmacopoeial microbial screen Confiscated counterfeit and unapproved drugs in Canada and Austria Above USP/EP limits in 23% of tested illegal Canadian samples and 6% in Austria (anabolic steroid & herbal drug) Pullirsch et al. (2014)

In an analytical chemistry study using validated liquid chromatography with UV detection and tandem mass spectrometry (LC-UV-MS/MS), Breindahl et al. (2015) assayed Melanotan II vials purchased from three online shops: although each shop claimed its vials contained 10 mg of Melanotan II, the measured total peptide mass per vial ranged from 4.32 to 8.84 mg—over a twofold spread—alongside 4.1% to 5.9% unknown impurities in vials from two shops (with impurities from the third shop below the quantification limit). Separately, a 2018 Belgian review (J Pharm Biomed Anal) named melanotan II among falsified image-enhancing polypeptides and noted seizures containing wrong active ingredients, wrong or absent doses, and unauthorized or failed clinical-trial peptides; the companion Talanta screening study quantified elevated inorganic arsenic and lead in ten frequently encountered falsified peptides on the Belgian market.

“For research purposes only” labels and U.S. compounding records

Patient-provided photographs in Vadner & Smith (2026) documented an online Melanotan II vial labeled “for research use only.” Dated agency advisories address such labels directly:

In the United States, two dated 2026 compounding records stand side by side. On its bulk drug substances safety page (content current as of April 22, 2026), FDA notes: “This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators,” and states: “Melanotan II: Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.” Alongside it, HHS's October 30, 2026 Federal Register notice (91 FR 68526) states: “The draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances does not establish any rights for any person and is not binding on HHS or the public,” and the draft policy text states: “Therefore, to expand and improve patient access while FDA reviews these substances, in the circumstances below, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A.” Appendix A lists six substances—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500—and does not include Melanotan II. Full dated agency texts appear in Dispatch 08.